The immunological basis of endotoxin-induced tumor regression. Requirement for a pre-existing state of concomitant anti-tumor immunity

doi:10.1084/jem.148.6.1560

This Article

	Full Text (PDF)
	Alert me when this article is cited
	Citation Map

Services

	Email this article
	Similar articles in this journal
	Similar articles in PubMed
	Alert me to new content in the JEM
	Download to citation manager

Citing Articles

	Citing Articles via HighWire
	Citing Articles via CrossRef
	Citing Articles via Google Scholar

Google Scholar

	Articles by Berendt, M. J.
	Articles by Kirstein, D. P.
	Search for Related Content

PubMed

	PubMed Citation
	Articles by Berendt, M. J.
	Articles by Kirstein, D. P.


Social Bookmarking

	What's this?

ARTICLES

The immunological basis of endotoxin-induced tumor regression. Requirement for a pre-existing state of concomitant anti-tumor immunity

MJ Berendt, RJ North and DP Kirstein

It was shown that of four syngeneic, murine tumors investigated, only those that evoked the generation of a state of concomitant anti-tumor immunity were susceptible to endotoxin-induced regression. Moreover, the temporal relationship between the generation of concomitant immunity and the onset of susceptibility to endotoxin-induced regression points to the likely possibility that tumor regression depends on the preceding acquisition of the specifically-sensitized, effector T cells that express concomitant immunity. It is suggested that endotoxin-induced hemorrhagic necrosis which invariably precedes tumor regression serves to create conditions inside the tumor that are conducive to the entry and the functioning of effector T cells. It is also suggested that tumor necrosis factor causes hemorrhagic necrosis rather than tumor regression.
Add to CiteULike CiteULike Add to Complore Complore Add to Connotea Connotea Add to Del.icio.us Del.icio.us Add to Digg Digg Add to Reddit Reddit Add to Technorati Technorati What's this?

This article has been cited by other articles:

Norton, J. A., Li, M., Lee, N. C., Tsung, K. (2006). Inhibition of Host Signal Transducer and Activator of Transcription Factor 6 Results in Cure With Cyclophosphamide and Interleukin 12 Immunotherapy. Ann. Surg. Oncol. 13: 118-124 [Abstract] [Full Text]
Turk, M. J., Guevara-Patino, J. A., Rizzuto, G. A., Engelhorn, M. E., Houghton, A. N. (2004). Concomitant Tumor Immunity to a Poorly Immunogenic Melanoma Is Prevented by Regulatory T Cells. J. Exp. Med. 200: 771-782 [Abstract] [Full Text]
Segal, J. G., Lee, N. C., Tsung, Y. L., Norton, J. A., Tsung, K. (2002). The Role of IFN-{gamma} in Rejection of Established Tumors by IL-12 : Source of Production and Target. Cancer Res. 62: 4696-4703 [Abstract] [Full Text]
Le, H. N., Lee, N. C., Tsung, K., Norton, J. A. (2001). Pre-Existing Tumor-Sensitized T Cells Are Essential for Eradication of Established Tumors by IL-12 and Cyclophosphamide Plus IL-12. J. Immunol. 167: 6765-6772 [Abstract] [Full Text]
Joseph, W. R., Cao, Z., Mountjoy, K. G., Marshall, E. S., Baguley, B. C., Ching, L.-M. (1999). Stimulation of Tumors to Synthesize Tumor Necrosis Factor-{{alpha}} in Situ Using 5,6-Dimethylxanthenone-4-acetic Acid: A Novel Approach to Cancer Therapy. Cancer Res. 59: 633-638 [Abstract] [Full Text]
Tsung, K., Meko, J. B., Tsung, Y. L., Peplinski, G. R., Norton, J. A. (1998). Immune Response Against Large Tumors Eradicated by Treatment with Cyclophosphamide and IL-12. J. Immunol. 160: 1369-1377 [Abstract] [Full Text]
Armstrong, T. D., Clements, V. K., Martin, B. K., Ting, J. P.-Y., Ostrand-Rosenberg, S. (1997). Major histocompatibility complex class II-transfected tumor cells present endogenous antigen and are potent inducers of�tumor-specific�immunity. Proc. Natl. Acad. Sci. USA 94: 6886-6891 [Abstract] [Full Text]